Homocysteine and risk of cardiovascular disease among postmenopausal women

Ridker, Paul M.; Manson, JoAnn E.; Buring, Julie E.; Shib, J.; Matias, Michelle Danielle Porto; Hennekens, C. H.

doi:10.3109/13697139909038077

Cited by 78 publications

(112 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elevated concentrations of Hcy (Boushey et al, 1995;Ridker et al, 1999), C-reactive protein (CRP) (Ridker et al, 1998(Ridker et al, , 2000 and vascular adhesion molecules (Hwang et al, 1997;Ridker et al, 2000) such as soluble E-selectin (sEselectin), soluble vascular adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1) have been associated with increased risk of CHD. Estrogen replacement therapy and the selective estrogen receptor modulator (SERM) raloxifene lower plasma Hcy (Walsh et al, 2000;Yildirir et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Consumption of isoflavone-rich soy protein does not alter homocysteine or markers of inflammation in postmenopausal women

et al. 2007

View full text Add to dashboard Cite

Background/Objective: To investigate the effect of soy protein containing isoflavones on homocysteine (Hcy), C-reactive protein (CRP), soluble E-selectin (sE-selectin), soluble vascular adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1). Subject/Methods: In a randomized crossover design, 34 postmenopausal women consumed soy protein isolate (2675 g protein containing 4478 mg isoflavones per day) or milk protein isolate (2675 g protein per day) for 6 weeks each. Fasting blood samples were collected at the end of each diet period and end points analyzed by enzyme-linked immunosorbent assay. Results: Concentrations of Hcy, CRP, sE-selectin, sVCAM-1 and sICAM-1 were not different between soy and milk diet treatments. Results did not differ by equol production status or by baseline lipid concentration. Adjustment for intake of folate and methionine did not alter the Hcy results. Conclusions: These data suggest that decreasing vascular inflammation and Hcy concentration are not likely mechanisms by which soy consumption reduces coronary heart disease risk.

show abstract

Section: Introductionmentioning

confidence: 99%

Consumption of isoflavone-rich soy protein does not alter homocysteine or markers of inflammation in postmenopausal women

et al. 2007

View full text Add to dashboard Cite

show abstract

“…An estimated 10-20% of all cardiovascular disease could be eliminated by simply lowering elevated Hcy levels, and studies show that simple key vitamins, such as folate and B12, are quite capable of doing so. These studies show a clear correlations between vitamin status and Hcy levels and that a combination of folate, B6, and B12 can lower Hcy by 50% (61)(62)(63)55,(64)(65)(66)(67)(68).…”

Section: N-acetyl Cysteine (Nac)mentioning

confidence: 68%

Connective tissue: Vascular and hematological (blood) support

Calvino

2003

Journal of Chiropractic Medicine

View full text Add to dashboard Cite

Connective Tissue (CT) is a ubiquitous component of all major tissues and structures of the body (50% of all body protein is CT), including that of the blood, vascular, muscle, tendon, ligament, fascia, bone, joint, IVD's (intervertebral discs) (eg, muscles, tendons, ligaments, fascia, bone, and joints), integument (skin) and inflammatory and immune mediation will be discussed here and will deal with connective tissue dynamics and dysfunction. An overview of the current scientific understanding and possible options for naturally enhancing the structure and function of CT through the application of these concepts will be discussed in this article, with specific attention on the vascular and hematological systems. (J Chiropr Med 2003;2:25-36)

show abstract

“…3,4 Our data describing a direct positive relation between homocysteine and subsequent vascular events within the AFCAPSA/Tex-CAPS cohort are consistent with most but not all prior studies of homocysteine and vascular risk. [5][6][7][8][9][10][11]17 Particular strengths of the present analysis that we believe increase its validity and generalizability include our large sample size, the use of a validated commercial assay for homocysteine assessment, and clear end point definitions and complete cohort ascertainment.…”

Section: Discussionmentioning

confidence: 99%

“…In several epidemiological studies, elevated homocysteine levels have been associated with increased risk of first [5][6][7][8] as well as recurrent myocardial infarction. [9][10][11] Partly on the basis of these observations, homocysteine screening also has been advocated as a method to improve detection of high-risk patients.…”

mentioning

confidence: 99%

Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events

Ridker¹,

Shih²,

Cook³

2002

ACC Current Journal Review

View full text Add to dashboard Cite

Background-Elevated homocysteine levels are associated with increased coronary risk, and it has been suggested that homocysteine screening may provide a method to identify high-risk patients for aggressive primary prevention. Methods and Results-Homocysteine was measured at baseline and after 1 year among 5569 participants in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), a randomized trial of lovastatin in the primary prevention of acute coronary events. The effects of homocysteine, LDL cholesterol, and lovastatin on risk were assessed over 5.2 years of trial follow-up. Median baseline homocysteine levels were significantly higher among study participants who subsequently had acute coronary events compared with those who did not (12.1 versus 10.9 mol/L, PϽ0.001). The relative risks of future events from lowest (referent) to highest quartile of homocysteine were 1.0, 1.6, 1.6, and 2.2 (PϽ0.001). These effects were similar among those allocated to lovastatin and those allocated to placebo and were modestly attenuated after adjustment for other traditional risk factors. As predicted, the subgroup of participants with elevated LDL cholesterol and elevated homocysteine levels were at high risk and benefited greatly from statin therapy (relative risk, 0.46; 95% CI, 0.29 to 0.75; number needed to treatϭ26). However, in contrast to findings in this trial for C-reactive protein, homocysteine evaluation did not help to define low LDL subgroups with different responses to lovastatin therapy. Conclusions-Although homocysteine predicted future coronary events in AFCAPS/TexCAPS, we found little evidence that homocysteine evaluation provided an improved method to target statin therapy among those with low-to-normal LDL cholesterol levels.

show abstract

Homocysteine and risk of cardiovascular disease among postmenopausal women

Abstract: Worldwfde literature review esters, oral tablets of testosterone derivatives, and transdermal patches. For most patients, androgen replacement therapy with testosterone is a safe, effective treatment for testosterone deficiency.

Cited by 78 publications

References 0 publications

Consumption of isoflavone-rich soy protein does not alter homocysteine or markers of inflammation in postmenopausal women

Consumption of isoflavone-rich soy protein does not alter homocysteine or markers of inflammation in postmenopausal women

Connective tissue: Vascular and hematological (blood) support

Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events

Contact Info

Product

Resources

About